Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 752 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cavities Clear all
Completed Phase 1 Interventional

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00003967
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
etoposide, topotecan hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Iowa City, Iowa • Baltimore, Maryland • Camden, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 3 Interventional

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

NCT00003809
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
73
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Early Phase 1 Interventional

Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck

NCT03238365
View directory record Official record
Conditions
Lip, Oral Cavity and Pharynx, Larynx
Interventions
Nivolumab, Tadalafil, Therapeutic Conventional Surgery
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 22, 2026, 4:14 PM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer

NCT00670397
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 22, 2026, 4:14 PM EDT
Terminated No phase listed Observational

Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer

NCT00898742
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
DNA and tissue microarray analysis, reverse transcriptase-polymerase chain reaction, mass spectrometry
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 2, 2013 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

MLN8237 in Head and Neck Cancer

NCT01540682
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
MLN8237, Cetuximab, Radiotherapy
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00083213
View directory record Official record
Conditions
Cancer
Interventions
ziv-aflibercept
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 22, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional

SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth

NCT00003223
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
fenretinide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
15
States / cities
Tucson, Arizona • Kansas City, Kansas • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Oct 22, 2026, 4:14 PM EDT
Not yet recruiting Phase 1 Interventional

Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma

NCT07335380
View directory record Official record
Conditions
Oral Cavity Squamous Cell Carcinoma
Interventions
Chemotherapy, Lattice Radiotherapy (LRT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer

NCT00448552
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
capecitabine, oxaliplatin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT01716715
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Cabozantinib S-malate, Laboratory Biomarker Analysis, Paclitaxel
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
173
States / cities
Mobile, Alabama • Burbank, California • Concord, California + 119 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat

NCT00012168
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
isosulfan blue, polymerase chain reaction, immunohistochemistry staining method, lymphangiography, radionuclide imaging, sentinel lymph node biopsy, technetium Tc 99m sulfur colloid
Drug · Genetic · Other + 2 more
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

NCT01673217
View directory record Official record
Conditions
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions
decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride, sargramostim, incomplete Freund's adjuvant, immunohistochemistry staining method, liquid chromatography, mass spectrometry, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, DNA methylation analysis, enzyme-linked immunosorbent assay
Drug · Biological · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Acceptability of Less Harmful Alternatives to Cigarettes

NCT00957424
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
telephone-based intervention, nicotine replacement therapy, informational intervention, internet-based intervention, questionnaire administration
Behavioral · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

NCT00357448
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
denileukin diftitox, intraperitoneal administration, laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
Biological · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00114153
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
capecitabine, carboplatin, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Oct 22, 2026, 4:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities

NCT05361941
View directory record Official record
Conditions
Periprosthetic Joint Infections
Interventions
EP Granules with Tobramycin, empty voids
Device
Lead sponsor
Elute, Inc.
Industry
Eligibility
22 Years and older
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Skokie, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 22, 2026, 4:14 PM EDT
Withdrawn Not applicable Interventional

Functional and Molecular Characterization of Treatment Response in Tumors in the Oral Cavity Using Optical Spectroscopy

NCT04272294
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Optical Spectroscopy
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 22, 2026, 4:14 PM EDT
Recruiting Not applicable Interventional

Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery

NCT07343596
View directory record Official record
Conditions
Oral Cavity Cancer
Interventions
Pembrolizumab, Patient-Specific Culture Vessel
Biological · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 4:14 PM EDT
Recruiting No phase listed Observational

Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

NCT05337631
View directory record Official record
Conditions
HNSCC, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer
Interventions
Not listed
Lead sponsor
University Hospital Freiburg
Other
Eligibility
65 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 22, 2026, 4:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

NCT05316688
View directory record Official record
Conditions
Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8
Interventions
Near Infrared Imaging, Therapeutic Conventional Surgery, Tozuleristide
Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00003385
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
7
States / cities
Honolulu, Hawaii • Iowa City, Iowa • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

NCT00077428
View directory record Official record
Conditions
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Adenoid Cystic Carcinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer
Interventions
bortezomib, doxorubicin hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 22, 2026, 4:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Probiotics That Moderate pH and Antagonize Pathogens to Promote Oral Health

NCT02999230
View directory record Official record
Conditions
Dental Caries
Interventions
Caries Free 1.5% Arginine, Caries Free Placebo Sodium Fluoride, Caries Active 1.5% Arginine, Caries Active- Placebo Sodium Fluoride
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 22, 2026, 4:14 PM EDT